This is a multicenter, randomized, open-label trial designed to evaluate the safety, feasibility, and efficacy of combining minimally invasive surgery (MIS) with intravenous deferoxamine (DFX) for the treatment of spontaneous intracerebral hemorrhage (ICH), compared to standard medical care.
This trial represents the first investigation of a dual-modality approach in ICH, integrating mechanical clot evacuation with biochemical neuroprotection, with the goal of improving neurological outcomes.

Start Date01 Mar 2026

Sponsor / Collaborator

University of Illinois

ChiCTR2600118673

/ SuspendedNot ApplicableIIT

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Exploratory Study of Deferoxamine Mesylate for the Treatment of Acute Intracerebral Hemorrhage

Start Date22 Feb 2026

Sponsor / Collaborator

Shanghai Huashan Hospital

NCT07023666

/ RecruitingPhase 2IIT

Early Detection and Management of Cardiac Iron Overload in Sickle Cell Disease Using Multimodal Imaging for Improved Clinical Outcomes

This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.

Start Date07 Oct 2025

Sponsor / Collaborator

Inova Health Care Services

100 Clinical Results associated with Deferoxamine Mesylate

100 Translational Medicine associated with Deferoxamine Mesylate

100 Patents (Medical) associated with Deferoxamine Mesylate

9,357

Literatures (Medical) associated with Deferoxamine Mesylate

31 Dec 2026·Journal of Oral Microbiology

Crosstalk between iron metabolism dysregulation and the oral microbiome in periodontitis

Review

Author: Liu, Haijie ; Pan, Yaping ; Li, Yuchao ; Zhang, Shuwei ; Lu, Ze ; Wang, Hongyan ; Yu, Zhenyuan

Background:

Periodontitis is a chronic inflammatory disease caused by periodontal pathogens. The impact of periodontitis is not only limited to the oral cavity, but also related to a variety of systemic diseases. Iron is a kind of redox metal, which may be deleterious to cells by producing damaging free radicals. Iron homeostasis dysregulation, especially ferroptosis, involves in the progression of periodontitis.

Objective:

This review aims to systematically summarize the crosstalk between iron metabolism dysregulation and the oral microbiome in periodontitis, focusing on alterations in iron-related biomarkers, iron-mediated tissue damage, the role of ferroptosis, and the potential of iron-targeted therapies.

Design:

A narrative review of recent advances in iron metabolism and ferroptosis, with emphasis on studies investigating molecular mechanisms, clinical correlations, and therapeutic interventions in periodontitis.

Results:

In periodontitis, serum iron and transferrin levels are decreased, while ferritin, hepcidin, and ceruloplasmin are elevated. Dysregulated iron metabolism promotes periodontal pathogen survival, amplifies inflammatory responses, induces ferroptosis in periodontal ligament cells, and contributes to alveolar bone resorption. Iron disorders also link periodontitis to systemic diseases such as anemia of inflammation, type 2 diabetes, and cardiovascular disease. Preclinical studies show that iron chelators (e.g. deferoxamine) and lactoferrin can inhibit bacterial growth, alleviate ferroptosis, and promote periodontal regeneration.

Conclusions:

Iron metabolism dysregulation and ferroptosis play critical roles in the initiation and progression of periodontitis and its systemic comorbidities. Targeting iron homeostasis represents a promising therapeutic strategy, but further well-designed clinical trials are needed to validate efficacy and safety.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Mechanisms and therapeutic strategies of ferroptosis in Diabetic-Associated Cognitive Dysfunction: focus on the crosstalk with apoptosis, autophagy, and pyroptosis

Review

Author: Jiang, Yayi ; Zhou, Jianlong ; Yue, Rensong ; Shi, Wenxiang

Diabetes-associated cognitive dysfunction (DACD), a serious central nervous system complication of diabetes mellitus, poses a heavy global burden due to its intricate pathogenesis and lack of effective therapies. Mounting evidence identifies programmed cell death (PCD) as a pivotal driver of DACD progression. This review systematically elaborates on the molecular mechanisms of various PCD modalities (including apoptosis, autophagy, pyroptosis, and ferroptosis) in DACD, with a particular focus on the role of ferroptosis as a core pathogenic mechanism. Hyperglycemia disrupts cerebral iron homeostasis, induces mitochondrial dysfunction and oxidative stress, leading to inhibition of glutathione peroxidase 4 (GPX4) activity and accumulation of lipid peroxides. This cascade ultimately triggers ferroptosis in neurons, glial cells, and the blood-brain barrier, resulting in impaired synaptic plasticity and cognitive decline. Furthermore, the review delineates the complex interactive regulatory network between ferroptosis and other PCD forms (e.g., autophagy, pyroptosis), which can converge into the coordinated cell death program of PANoptosis. Intervention strategies targeting ferroptosis, such as iron chelators (deferoxamine), antioxidants (N-acetylcysteine), GPX4 activators, natural products (resveratrol, curcumin), repurposed traditional medicines (liraglutide, metformin), and non-pharmaceutical interventions (exercise, electroacupuncture), have demonstrated significant potential in improving cognitive function in preclinical models. This review aims to provide novel insights into the pathophysiology of DACD and establish a theoretical foundation for developing precise therapeutic strategies centered on targeting ferroptosis.

01 Oct 2026·TISSUE & CELL

Local stabilization of HIF-1α via deferoxamine-loaded collagen–chitosan sponge scaffold accelerates healing of type 2 diabetic wounds in rats

Article

Author: Alghamdi, Amani ; Altarjami, Lamaia R ; Abalkhail, Adil ; Juraybi, Tawfiq N ; Alissa, Mohammed ; Binshaya, Abdulkarim S ; Alshaghdali, Khalid ; Alghamdi, Suad A

Diabetic wounds are characterized by impaired angiogenesis, prolonged inflammation, and delayed tissue regeneration, which often result in chronic non-healing ulcers. Hypoxia-inducible factor-1 alpha (HIF-1α) signaling plays a critical role in coordinating angiogenesis and tissue repair; however, its activity is markedly suppressed in diabetic conditions. This study aimed to evaluate the therapeutic efficacy of a collagen-chitosan sponge scaffold (CoChSS) loaded with deferoxamine (DFO) in enhancing diabetic wound healing through modulation of the hypoxic microenvironment and activation of angiogenic pathways. Type 2 diabetic rats were randomly assigned to three groups: untreated control, CoChSS scaffold alone, and DFO-loaded CoChSS (CoChSS/DFO). Full-thickness excisional wounds were created, and healing outcomes were evaluated on days 4 and 8 post-injury. Wound closure rate, mechanical properties, stereological parameters (fibroblast density, blood vessel density, and inflammatory cell infiltration), collagen deposition, gene expression (HIF-1α and SDF-1α, VEGF, TGF-β, TNF-α, IL-1β), and oxidative stress markers (CAT, SOD, GSH, and MDA) were systematically assessed. The CoChSS/DFO group exhibited significantly accelerated wound closure compared with both control and scaffold-only groups (P < 0.05). Mechanical testing demonstrated enhanced tensile strength and energy absorption in regenerated tissue following CoChSS/DFO treatment (P < 0.05). Stereological analysis revealed markedly increased angiogenesis and fibroblast proliferation, accompanied by a significant reduction in inflammatory cell infiltration (P < 0.05). Histological evaluation using Masson's trichrome staining showed enhanced collagen deposition and improved matrix organization in the CoChSS/DFO group (P < 0.05). At the molecular level, CoChSS/DFO significantly upregulated HIF-1α, SDF-1α, VEGF, and TGF-β expression, while suppressing pro-inflammatory cytokines TNF-α and IL-1β (P < 0.05). Additionally, antioxidant enzyme activities were elevated and lipid peroxidation was reduced, indicating effective mitigation of oxidative stress (P < 0.05). In conclusion, the DFO-loaded CoChSS scaffold promotes diabetic wound healing through a multimodal mechanism involving hypoxia signaling activation, angiogenesis enhancement, inflammation attenuation, oxidative stress reduction, and improved extracellular matrix remodeling. This strategy represents a promising therapeutic platform for the treatment of chronic diabetic wounds.

News (Medical) associated with Deferoxamine Mesylate

07 May 2026

·www.biospace.com

KORU Medical Systems Announces First Quarter 2026 Results

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2026. The Company also reiterated guidance for the full year 2026. Recent Highlights First quarter 2026 net revenues of $11.8 million grew 22% over the prior year period First quarter 2026 gross profit grew 20% over the prior year period to $7.2 million, with gross margin of 61.5% First quarter 2026 net loss improved 31% to ($0.8) million Ending cash balance of $8.8 million reflects cash usage of approximately $0.1 million in the first quarter of 2026 Submitted 510(k) application for use of the Freedom Infusion System with Deferoxamine Two existing non-Ig pharma collaborations advanced to Phase III clinical trials “We are proud to deliver a record start to 2026, with $11.8 million in revenue, representing 22% growth,” said Linda Tharby, CEO of KORU Medical. “Our Core business continues to outperform the underlying SCIg market, driven by increased share gains in current and new accounts. Internationally, momentum remains robust as we expand into prefilled syringe markets with our patient-preferred Freedom Infusion System. With a growing recurring patient base and scalable commercial model, KORU is well positioned for further success.” Adam Kalbermatten, President and Chief Commercial Officer, added, "Equally exciting to our strength in core markets is the momentum we are building in new drug categories with our support of late-stage molecules through their regulatory pathways, including compelling oncology opportunities ahead. A strong team, a clear strategic roadmap, and an expanding platform to access new therapies and new geographies, makes me confident in our long-term strategy and the strong foundation we have built to execute." 2026 First Quarter Financial Results Three Months Ending March 31, Change from Prior Year % of Net Revenues 2026 2025 $ % 2026 2025 Net Revenues Domestic Core $ 7,739,872 $ 6,927,964 $ 811,908 11.7% 65.8% 71.9% International Core 3,284,041 2,428,662 855,379 35.2% 27.9% 25.2% Total Core 11,023,913 9,356,626 1,667,287 17.8% 93.7% 97.1% Pharma Services and Clinical Trials 740,711 278,449 462,262 166.0% 6.3% 2.9% Total $ 11,764,624 $ 9,635,075 $ 2,129,549 22.1% 100% 100% Total net revenues increased $2.1 million, or 22.1%, to $11.8 million for the three months ending March 31, 2026, as compared to $9.6 million in the prior year period. Domestic core revenues were $7.7 million, an increase of 11.7% over the prior year period, primarily due to higher consumable volumes, driven by new patient starts and market share gains within new and existing accounts, supported by a strong underlying SCIg market. International core revenues were $3.3 million, an increase of 35.2% over the prior year period, primarily due to higher pump and consumable volumes, driven by distributor purchases supporting pre-filled syringe (PFS) conversions for a key EU market. Pharma services and clinical trials net revenues were $0.7 million, an increase of 166.0% over the prior year period, primarily due to higher clinical trial product revenues for advancing existing collaborations. Gross profit increased $1.2 million, or 19.6%, to $7.2 million in the three months ending March 31, 2026, as compared to $6.0 million in the prior year period. Gross margin decreased to 61.5% in the three months ending March 31, 2026, as compared to 62.8% in the prior year period. The decrease in gross margin was primarily driven by higher production costs based on timing of production runs in the prior quarter that were amortized in the three months ended March 31, 2026, and tariff-related charges that did not occur in the prior year period, partially offset by a favorable geographic sales mix. Total operating expenses increased $0.8 million, or 11.0%, to $8.1 million for the first quarter of 2026 primarily driven by an increase of $0.6 million in selling, general, and administrative expenses, and an increase of $0.2 million in research and development expenses. The increase in selling, general and administrative expenses was primarily driven by increases in legal fees and compensation expenses related to salary and stock compensation, partially offset by lower temporary labor expenses. Net loss decreased $0.4 million to $0.8 million or ($0.02) per diluted share for the first quarter of 2026, compared to a net loss of $1.2 million, or ($0.03) per diluted share, for the prior year period. Adjusted EBITDA for the quarter was ($0.01) million, or $0.00 per diluted share versus ($0.2) million or ($0.00) per diluted share in the prior year period. A reconciliation of adjusted EBITDA and adjusted diluted EPS to the most directly comparable GAAP measures is provided at the end of this press release. Cash and cash equivalents were $8.8 million as of March 31, 2026, reflecting cash usage of $0.1 million in the first quarter of 2026. Reiterating 2026 Guidance KORU Medical expects: Reiterating full year 2026 net revenues between $47.5 - $50.0 million, representing growth of 15% - 22% Reiterating full year 2026 gross margin between 61 - 63% Reiterating positive adjusted EBITDA and positive cash flow for the full year 2026 Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Wednesday, May 6, 2026, at 4:30 PM ET. To participate in the call, please dial (877) 407-0784 (domestic) or (201) 689-8560 (international). The live webcast will be available on the IR Calendar on the News/Events page of the Investors section of KORU Medical’s website. Non-GAAP Measures This press release includes the non-GAAP financial measures “adjusted diluted EPS” and “adjusted EBITDA” that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on KORU Medical’s reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company’s financial results. Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with GAAP financial results. Reconciliations of the Company’s non-GAAP measures are included at the end of this press release. About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the Freedom60 ® and FreedomEDGE ® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Service and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit . Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements, including, but not limited to, financial guidance and expected operating performance for fiscal 2026. Forward-looking statements discuss the Company’s current expectations and projections relating to its financial position, results of operations, plans, objectives, future performance, and business. Forward-looking statements can be identified by words such as “guidance”, “expect” and “will”. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, uncertainties associated with inflation, tariffs, war and other geopolitical conflicts, customer ordering patterns, availability and costs of raw materials and labor and our ability to recover such costs, future operating results, growth of new patient starts and the Ig market, our compliance with Food and Drug Administration and foreign authority regulations and the outcome of regulatory audits, introduction and adoption of competitive products, acceptance of and demand for new and existing products, ability to penetrate new markets, success in enforcing and obtaining patents, reimbursement related risks, government regulation of the home health care industry, success of our research and development effort, expanding the market of the Freedom System, demand in the SCIg market, availability of sufficient capital if or when needed, dependence on key personnel, the impact of recent accounting pronouncements, and those risks and uncertainties included under the captions “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, which is on the SEC and available on our website at and on the SEC website at . All information provided in this release and in the attachments is as of May 6, 2026. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law. KORU MEDICAL SYSTEMS, INC. BALANCE SHEETS March 31, December 31, 2026 2025 (UNAUDITED) ASSETS CURRENT ASSETS Cash and cash equivalents $ 8,767,774 $ 8,872,212 Accounts receivable 5,982,536 6,209,950 Inventory, net 4,476,304 3,678,131 Other receivables 335,206 319,955 Prepaid expenses 1,026,614 908,542 TOTAL CURRENT ASSETS 20,588,434 19,988,790 Property and equipment, net 4,335,882 4,471,386 Intangible assets, net of accumulated amortization of $545,302 and $527,949 as of March 31, 2026 and December 31, 2025, respectively 711,211 684,841 Operating lease right-of-use assets 2,857,341 2,956,192 Other assets 98,970 98,970 TOTAL ASSETS $ 28,591,838 $ 28,200,179 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable $ 2,635,701 $ 2,267,473 Accrued expenses 5,271,100 4,828,830 Other liabilities 11,068 27,722 Accrued payroll and related taxes 385,890 531,972 Financing lease liability 126,323 124,913 Operating lease liability 421,727 413,448 TOTAL CURRENT LIABILITIES 8,851,809 8,194,358 Financing lease liability, net of current portion 46,560 78,675 Operating lease liability, net of current portion 2,771,115 2,879,224 TOTAL LIABILITIES 11,669,484 11,152,257 STOCKHOLDERS’ EQUITY Common stock, $0.01 par value, 75,000,000 shares authorized, 49,933,502 and 49,790,934 shares issued 46,133,000 and 46,370,432 shares outstanding as of March 31, 2026, and December 31, 2025, respectively 499,335 497,909 Additional paid-in capital 54,795,722 52,449,339 Treasury stock, 3,818,526 and 3,438,526 shares as of March 31, 2026 and December 31, 2025, respectively, at cost (5,548,793 ) (3,882,494 ) Accumulated deficit (32,823,910 ) (32,016,832 ) TOTAL STOCKHOLDERS’ EQUITY 16,922,354 17,047,922 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 28,591,838 $ 28,200,179 KORU MEDICAL SYSTEMS, INC. STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended March 31, 2026 2025 NET REVENUES $ 11,764,624 $ 9,635,075 Cost of goods sold 4,533,235 3,588,740 Gross Profit 7,231,389 6,046,335 OPERATING EXPENSES Selling, general and administrative 6,582,178 5,959,374 Research and development 1,316,603 1,114,609 Depreciation and amortization 197,531 217,357 Total Operating Expenses 8,096,312 7,291,340 Net Operating Loss (864,923 ) (1,245,005 ) Non-Operating Income/(Expense) Gain/(Loss) on currency exchange (23,150 ) 5,588 Interest income, net 80,995 73,180 TOTAL OTHER INCOME 57,845 78,768 LOSS BEFORE INCOME TAXES (807,078 ) (1,166,237 ) Income Tax Refund (Expense) — — NET LOSS $ (807,078 ) $ (1,166,237 ) NET LOSS PER SHARE Basic & Diluted $ (0.02 ) $ (0.03 ) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Basic & Diluted 46,364,905 45,981,826 KORU MEDICAL SYSTEMS, INC. STATEMENTS OF CASH FLOWS (UNAUDITED) For the Three Months Ended March 31, 2026 2025 CASH FLOWS FROM OPERATING ACTIVITIES Net Loss $ (807,078 ) $ (1,166,237 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense and warrant expense 681,510 697,590 Depreciation and amortization 197,531 217,357 Non-cash leasing charges (979 ) — Changes in operating assets and liabilities: Accounts receivable 227,414 (228,661 ) Inventory (798,173 ) (474,977 ) Prepaid expenses and other assets (133,323 ) (8,094 ) Other liabilities (16,655 ) 80,828 Accounts payable 368,228 363,608 Accrued payroll and related taxes (146,081 ) 227,316 Accrued expenses 442,269 53,803 NET CASH FROM/(USED IN) OPERATING ACTIVITIES 14,663 (237,467 ) CASH FLOWS FROM INVESTING ACTIVITIES Purchases of property and equipment (46,163 ) (443,438 ) Purchases of intangible assets (43,722 ) (3,400 ) NET CASH USED IN INVESTING ACTIVITIES (89,885 ) (446,838 ) CASH FLOWS FROM FINANCING ACTIVITIES Payments on insurance finance indebtedness — (133,973 ) Payments on finance lease liability, net of asset (29,216 ) (26,835 ) NET CASH USED IN FINANCING ACTIVITIES (29,216 ) (160,808 ) NET DECREASE IN CASH AND CASH EQUIVALENTS (104,438 ) (845,113 ) CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 8,872,212 9,580,947 CASH AND CASH EQUIVALENTS, END OF PERIOD $ 8,767,774 $ 8,735,834 Supplemental Information Cash paid during the periods for: Interest $ 2,155 $ 5,385 KORU MEDICAL SYSTEMS, INC. SUPPLEMENTAL INFORMATION (UNAUDITED) A reconciliation of our non-GAAP measures is below: Three Months Ended Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA: March 31, 2026 2025 GAAP Net Loss $ (807,078 ) $ (1,166,237 ) Depreciation and Amortization* 197,531 217,357 Interest (Income), Net (80,996 ) (73,180 ) Litigation Expense - 133,411 Stock-based Compensation Expense* 681,510 697,590 Adjusted EBITDA $ (9,032 ) $ (191,059 ) Weighted average number of common shares 46,364,905 45,981,826 Three Months Ended Reconciliation of Reported Diluted EPS to Non-GAAP Adjusted Diluted EPS: March 31, 2026 2025 Reported Diluted Earnings Per Share $ (0.02 ) $ (0.03 ) Depreciation and Amortization* 0.00 0.00 Interest (Income), Net (0.00 ) (0.00 ) Litigation Expense - 0.00 Stock-based Compensation Expense* 0.01 0.02 Adjusted Diluted Earnings Per Share $ (0.00 ) $ (0.00 ) *Numbers presented are rounded to the nearest whole cent and percentage Stock-based Compensation Expense . We have excluded the effect of stock-based compensation expense in calculating our non-GAAP measures. We record non-cash compensation expenses related to grants of options and restricted shares for executives, employees and consultants, and grants of shares to our board of directors. Depending upon the size, timing and the terms of the grants, the non-cash compensation expense may vary significantly but will recur in future periods. Litigation Expense. We have excluded the effect of start-up litigation expense in calculating our non-GAAP measures. In the first quarter 2025 we incurred legal fees with respect to a claim filed by the Company alleging patent infringement, which we would not have otherwise incurred in the period presented as part of continuing operations. Contacts Investor Contact: Louisa Smith investor@korumedical.com

04 Sep 2025

·www.globenewswire.com

BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference

Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE), a clinical-stage company advancing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that Jonathan Solomon, the Company’s Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference taking place on September 7-9, 2025, at the Lotte New York Palace Hotel in New York City. The presentation, titled "Phage Therapy: A Novel Approach to Chronic Diabetic Foot Infections," will take place on September 8th from 4:30 - 5:00 PM ET. The presentation will focus on positive topline results from the Company's Phase 2 trial evaluating BX211 for the treatment of DFO. Investors attending the event may request a one-on-one meeting with BiomX through their H.C. Wainwright representative or e-mail meetings@hcwco.com. About BX211BX211 is a phage treatment for the treatment of DFO associated with S. aureus. DFO is a bacterial infection of the bone that usually develops from an infected foot ulcer and is a leading cause of amputation in patients with diabetes. In March 2025, BiomX announced positive topline results from the Phase 2 trial in which BX211 was demonstrated to be safe and well-tolerated and patients receiving BX211 exhibited statistically significant1 and sustained reduction of ulcer size (PAR)(p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10. In addition, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline, ulcer depth was classified according to deepest tissue involved as measured by swab) (p=0.048), and in reducing the expansion of ulcer area (p=0.017). Over the 12-week treatment period, all patients (treatment and placebo) were treated in accordance with standard of care, including with systemic antibiotic therapy as appropriate. BiomX is currently planning a registrational trial, pending discussions and feedback from the Food and Drug Administration (FDA). About BiomXBiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release. Safe HarborThis press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX refers to its anticipated timing of its future clinical trials as well as the design thereof, expected discussions with the FDA and results thereof, and the potential of its candidates to address the substantial unmet needs of patients with chronic diseases, it is using forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX’s control. These risks and uncertainties include, but are not limited to, changes in applicable laws or regulations; the possibility that BiomX may be adversely affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in BiomX’s drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials, BiomX’s ability to enroll patients in its clinical trials, and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all; decisions made by the FDA and other regulatory authorities; decisions made by investigational review boards at clinical trial sites and publication review bodies with respect to BiomX’s development candidates; BiomX’s ability to obtain, maintain and enforce intellectual property rights for its platform and development candidates; its potential dependence on collaboration partners; competition; uncertainties as to the sufficiency of BiomX’s cash resources to fund its planned activities for the periods anticipated and BiomX’s ability to manage unplanned cash requirements; and general economic and market conditions. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 25, 2025, and additional disclosures BiomX makes in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements. Contacts: BiomX, Inc.Ben CohenHead Corporate Communicationsbenc@biomx.com 1 All p-values described in this release are non-adjusted

Clinical ResultPhase 2

13 Aug 2025

·www.globenewswire.com

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communications publication of new BX004 Phase 1b/2a data demonstrated further ~500-fold (2.7 log₁₀)2 bacterial reduction versus placebo with no detectable emergence of resistance observed, highlighting strength of BiomX platform capabilitiesPhase 2b trial of BX004 in Cystic Fibrosis (CF) has successfully commenced patient dosing; FDA feedback on real-world evidence strategy expected in H2 2025; Company expects to report topline results in Q1 2026 BiomX will host a conference call and webcast today at 8:00 AM ET NESS ZIONA, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced financial results for the second quarter ended June 30, 2025, and provided recent clinical and corporate updates. “In the past few months, BiomX achieved several significant milestones that advance our pipeline and further validate our phage therapy platform,” said Jonathan Solomon, Chief Executive Officer of BiomX. “Positive Phase 2 results for BX211 in diabetic foot osteomyelitis demonstrated sustained, statistically significant improvements in wound size reduction, with over 40% reduction in ulcer size compared to placebo, and a favorable safety profile. In parallel, new peer-reviewed data for BX004, published in Nature Communications, reported approximately 500-fold (2.7 log₁₀)2 further bacterial reduction versus placebo and no detectable emergence of resistance, critical evidence supports the strength of our candidate BX004. With BX004’s Phase 2b trial now underway, FDA feedback on our real-world evidence plan expected later this year, and planning for a potential registrational BX211 study in progress, BiomX is positioned for multiple value-driving catalysts over the next 12 months.” Clinical Program Updates BX211 – Phage for the treatment of patients with diabetic foot infections and osteomyelitis (DFI/DFO) associated with Staphylococcus aureus (S. aureus) BiomX reported positive topline results from the Phase 2 trial of BX211 in March 2025 just prior to the start of the second quarter, demonstrating that BX211 was safe and well-tolerated and produced sustained and statistically significant1 percentage area reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13) with separation from placebo starting at week 7 and a difference greater than 40% by week 10.The Phase 2 trial results also showed that BX211 produced statistically significant improvements in both ulcer depth at week 13 in patients with ulcer depth defined as bone exposure at baseline (p=0.048) and in reducing the expansion of ulcer area (p=0.017) compared to placebo, with all patients receiving standard of care including systemic antibiotic therapy as appropriate over the 12-week treatment period. Planning for a potential registrational study of BX211 is underway, pending feedback from the U.S. Food and Drug Administration (FDA).Following strong Phase 2 results, the Company hosted a Virtual Key Opinion Leader event during the second quarter featuring leading clinical experts in diabetic foot infections and osteomyelitis. The discussion highlighted the clinical significance of the BX211 data, its potential role alongside standard of care, and perspectives on the path to registrational development. A replay of the webcast is available at the following Link, the content of which does not form a part of this press release.The Company is in continued discussions with the U.S. Defense Health Agency regarding next steps for the BX211 program following the positive Phase 2 results. BX004 – Fixed phage cocktail for chronic Pseudomonas aeruginosa (P. aeruginosa) in patients with CF In July 2025, BiomX successfully initiated dosing of patients in its Phase 2b trial of BX004. The Phase 2b trial is a randomized, double-blind, placebo-controlled, multicenter study in approximately 60 CF patients with chronic P. aeruginosa infections. Patients are randomized 2:1 to receive either BX004 or placebo via inhalation twice daily for 8 weeks. The trial is designed to measure multiple efficacy endpoints, including reduction in bacterial burden, improvements in lung function, and enhanced quality of life as measured by validated patient questionnaires.The Company expects to report topline results from the Phase 2b study in the first quarter of 2026.In the second half of 2025, BiomX expects to receive feedback from the FDA regarding the potential investigation and use of real-world evidence linking bacterial reduction to clinical outcomes. Successful alignment could potentially streamline approval pathway.Earlier in July, Nature Communications published new findings from the Company’s Phase 1b/2a trial, showcasing previously unreported antimicrobial efficacy data showing that BX004 achieved a substantially greater improvement of approximately 500-fold (2.7 log₁₀)2 in bacterial reduction compared with placebo in CF patients. The data also highlight that no bacterial resistance to BX004 was detected during the trial, and also detailed in the article are BiomX’s innovative approach to large-scale data analysis in order to optimize bacteriophage cocktails. Second Quarter 2025 Financial Results Cash balance and restricted cash as of June 30, 2025, were $15.2 million, compared to $18 million as of December 31, 2024. The decrease was primarily due to net cash used in operating activities. BiomX estimates its cash, cash equivalents and restricted cash are sufficient to fund its operations into the first quarter of 2026. Research and development expenses, net were $5.0 million for the second quarter of 2025, compared to $6.9 million for the second quarter of 2024. The decrease was primarily driven by: reduced salary expenses from workforce reductions; lower rent expenses following a right-of-use asset impairment in 2024; and increased grant funding from the Medical Technology Enterprise Consortium (under the DHA) and the Israel Innovation Authority. This was partially offset by higher expenses from initiating the Phase 2b clinical trial of the Company’s CF product candidate, BX004. General and administrative expenses were $2.4 million for the second quarter of 2025, compared to $2.8 million for the second quarter of 2024. The decrease was primarily attributed to a reduction in legal and other professional service fees, partially offset by increased share-based compensation expenses. Net loss was $6.0 million for the second quarter of 2025, compared to income of $4.5 million for the second quarter of 2024. The decrease was mainly due to the change in the fair value of warrants issued as part of the Company’s March 2024 financing. Net cash used in operating activities for the six months ended June 30, 2025, was $14.8 million, compared to $22.6 million for the same period in 2024. Conference Call and Webcast Details BiomX will host a conference call and webcast on August 13, 2025, at 8 AM ET to discuss its second quarter 2025 financial results and to provide a corporate update. Conference Callhttps://register-conf.media-server.com/register/BI35d84b315cb147c78290b6b8f1fde487 Webcast Link https://edge.media-server.com/mmc/p/89dfoxpe/ About BX211BX211 is a phage treatment for the treatment of DFO associated with S. aureus. DFO is a bacterial infection of the bone that usually develops from an infected foot ulcer and is a leading cause of amputation in patients with diabetes. In March 2025, BiomX announced positive topline results from the Phase 2 trial in which BX211 was demonstrated to be safe and well-tolerated and patients receiving BX211 exhibited statistically significant1 and sustained reduction of ulcer size (PAR)(p=0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10. In addition, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline, ulcer depth was classified according to deepest tissue involved as measured by swab) (p=0.048), and in reducing the expansion of ulcer area (p=0.017). Over the 12-week treatment period, all patients (treatment and placebo) were treated in accordance with standard of care, including with systemic antibiotic therapy as appropriate. BiomX is currently planning a potential registrational study pending discussions and feedback from the FDA, and availability of cash resources. About BX004BiomX is developing BX004, a fixed multi-phage cocktail, for the treatment of CF patients with chronic pulmonary infections caused by P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. In February 2023, BiomX announced positive results from Part 1 of the Phase 1b/2a study, showing safety, tolerability, and microbiologic activity. In November 2023, BiomX announced positive topline results from Part 2 of the Phase 1b/2a trial, in which BX004 demonstrated improvement in pulmonary function associated with a reduction in P. aeruginosa burden compared to placebo in a predefined subgroup of patients with reduced lung function (baseline FEV1<70%). BiomX is now enrolling up to approximately 60 patients in a randomized, double blind, placebo-controlled, multi center Phase 2b trial of BX004 in CF patients with chronic P. aeruginosa lung infections. The 8-week study will assess lung function, bacterial load, and quality of life metrics. BX004 has received FDA Fast Track and Orphan Drug Designations. About BiomXBiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release. Safe HarborThis press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX refers to its anticipated timing for reporting results for its clinical assets as well as the design of clinical trials thereof, future catalysts, potential timing and outcome of expected feedback from the FDA and discussions with the U.S. Defense Health Agency, the potential safety, efficacy and toleration of BX004 and BX211, the potential benefits of BX004 and BX211, future clinical development of BX004 and BX211, including conducting a registrational trial in BX211, the potential of its candidates to address the substantial unmet needs of patients, and the estimates of the sufficiency of its cash, cash equivalents and short-term deposits, it is using forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX’s control. These risks and uncertainties include, but are not limited to, changes in applicable laws or regulations; the possibility that BiomX may be adversely affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in BiomX’s drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials, BiomX’s ability to enroll patients in its clinical trials, and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all; decisions made by the FDA, and other regulatory authorities; decisions made by investigational review boards at clinical trial sites and publication review bodies with respect to our development candidates; BiomX’s ability to obtain, maintain and enforce intellectual property rights for its platform and development candidates; its potential dependence on collaboration partners; competition; uncertainties as to the sufficiency of BiomX’s cash resources to fund its planned activities for the periods anticipated and BiomX’s ability to manage unplanned cash requirements; and general economic and market conditions. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 25, 2025, and additional disclosures BiomX makes in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements. Contacts:BiomX, Inc.Ben CohenHead Corporate Communicationsbenc@biomx.com 1 All p-values described in this release are non-adjusted2 A 2.7 log₁₀ reduction represents a 10^2.7 = ~500-fold reduction in bacterial load, which equates to approximately 99.8% reduction. BIOMX INC.CONDENSED CONSOLIDATED BALANCE SHEETS(USD in thousands, except share and per share data)(unaudited) As of June 30, 2025 December 31, 2024 ASSETS Current assets Cash and cash equivalents 14,046 16,856 Restricted cash 979 958 Other current assets 1,610 2,706 Total current assets 16,635 20,520 Non-current assets Non-current restricted cash 161 161 Operating lease right-of-use assets 4,959 5,457 Property and equipment, net 4,245 5,045 In-process Research and development asset 12,050 12,050 Total non-current assets 21,415 22,713 38,050 43,233 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Trade accounts payable 2,178 1,882Current portion of lease liabilities 1,233 1,130Other accounts payable 2,851 5,255Total current liabilities 6,262 8,267 Non-current liabilities Operating lease liabilities, net of current portion 8,143 8,454Other liabilities 80 77Warrants 4,405 2,287Total non-current liabilities 12,628 10,818 Commitments and Contingencies (Note 6) Stockholders’ equity Preferred Stock, $0.0001 par value; Authorized – 1,000,000 shares as of June 30, 2025 and December 31, 2024. Issued and outstanding- 147,735 as of June 30, 2025 and December 31, 2024. 18,645 18,645Common Stock, $0.0001 par value; Authorized – 750,000,000 shares as of June 30, 2025 and December 31, 2024. Issued and outstanding- 26,443,257 shares as of June 30, 2025 and 18,176,661 shares as of December 31, 2024. 7 6 Additional paid in capital 194,901 186,194Accumulated deficit 194,393)) (180,697Total stockholders’ equity 19,160 24,148 38,050 43,233 BIOMX INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(USD in thousands, except share and per share data)(unaudited) Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 20252024 Research and development (“R&D”) expenses, net 5,014 6,897 10,26411,002General and administrative expenses 2,419 2,828 4,9255,508 Operating loss 7,433 9,725 15,18916,510 Other expenses (income) 70 (2,017) 76(2,105)Interest expenses 5 13 10863Income from change in fair value of warrants 1,498)( (11,868) (2,412)(3,858)Finance expense (income), net 25 (329) 8301,436Loss (income) before tax 6,035 (4,476) 13,69312,846 Tax expenses 2 5 310 Net loss (income) 6,037 (4,471) 13,69612,856 Basic loss (earnings) per share of Common Stock 0.19 (0.14) 0.501.95Diluted loss per share of Common Stock 0.19 0.69 0.501.95 Weighted average number of shares used in computing basic loss (earnings) pershare of Common Stock 31,308,396 6,980,943 27,250,021 6,605,952Weighted average number of shares used in computing diluted loss per share ofCommon Stock 31,308,396 10,750,194 27,250,021 6,605,952

Clinical ResultPhase 2Fast TrackOrphan DrugFinancial Statement

100 Deals associated with Deferoxamine Mesylate

External Link

KEGG	Wiki	ATC	Drug Bank
D01186	Deferoxamine Mesylate	V03AC01	DB00746

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Fibrosis, Liver	Australia	Demo S.A. Pharmaceutical Industry	09 Apr 2026
Thalassemia	Australia	Demo S.A. Pharmaceutical Industry	09 Apr 2026
Chronic iron overload	United States	Mitem Pharma SAS	01 Apr 1968
Iron Overload	United States	Mitem Pharma SAS	01 Apr 1968

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic ulcer	Phase 2	United States	Tautona Group	21 Jul 2020
Leg Ulcer	Phase 2	United States	Tautona Group	21 Jul 2020
Skin Ulcer	Phase 2	United States	Tautona Group	21 Jul 2020
Beta-Thalassemia	Phase 2	Greece	Novartis Pharmaceuticals Corp.	01 Jan 2011
Transfusion-dependent Beta Thalassemia	Phase 2	Greece	Novartis Pharmaceuticals Corp.	01 Jan 2011
Anemia, Sickle Cell	Phase 2	United States	Novartis Pharmaceuticals Corp.	01 May 2003
Hemosiderosis	Phase 2	United States	Novartis Pharmaceuticals Corp.	01 May 2003
Metastatic Malignant Neoplasm to the Leptomeninges	Phase 1	United States	Memorial Sloan Kettering Cancer Center	22 Dec 2021
Metabolic dysfunction-associated steatotic liver disease	Preclinical	China	Chinese Academy of Sciences	28 Dec 2025
Muscular Atrophy	Preclinical	South Korea	Suwon University	20 Jun 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04633889 (DEFEAT-AKI, CTgov)	Phase 2	Acute Kidney Injury	320	Deferoxamine (Deferoxamine)	wcsftgagnf = lduleqifxp dlucetysdx (zoglrlpnhl, wughwruitf - rbmtqfjtyc) View more	-	26 Jan 2026
				Normal saline (Placebo)	wcsftgagnf = qpitdswqca dlucetysdx (zoglrlpnhl, wmatuvctpm - ebpneidnzz) View more
NCT02175225 (i-DEF, Pubmed \| Int J Stroke)	Phase 2	Cerebral Hemorrhage	291	Deferoxamine	aodlenflmz(qlwpeiilgy) = twsmmwibgq nifpupdzaa (gnkiiypgts ) View more	Positive	01 Dec 2025
				Placebo	aodlenflmz(qlwpeiilgy) = nwnvyibivz nifpupdzaa (gnkiiypgts ) View more
NCT05184816 (Phase 1a analysis, ASCO2025)	Phase 1	Metastatic Malignant Neoplasm to the Leptomeninges lipocalin-2/SLC22A17	8	Intrathecal deferoxamine (IT-DFO) 10 mg	koiqsigfdd(dztwotzviy) = median overall survival for the evaluable cohort (n = 7) was 10.0 months (95% CI, 6.5 - NA) tbhybvtlyr (qsjmrqldxo ) View more	Positive	30 May 2025
				Intrathecal deferoxamine (IT-DFO) 30 mg
NCT00901199 (CTgov)	Phase 2	Transfusion-dependent Thalassemia \| Iron Overload \| Thalassemia	22	Deferasirox+Deferoxamine	tndropwsld(swvbglvkyu) = snnfgdoyph tvgxwqpwqe (qsyuquiurq, qgzxepxozt - zgxendpddo) View more	-	12 Aug 2021
NCT01254227 (HYPERION, CTgov)	Phase 2	Iron Overload	60	Deferasirox (DFX)+Deferoxamine+DFX	unpeyxmnpx(dyjfwmdjxc) = abbrvdmxjc yjfhsgmpbq (gyrlyvodrz, dwncltibnk - ogsntiieke) View more	-	24 Jun 2021
NCT01459718 (CTgov)	Phase 2	Beta-Thalassemia \| Iron Overload \| Transfusion-dependent Beta Thalassemia	32	Deferasirox+Deferoxamine (DFO)	gxcceovntl = ewxwjslpzs dffwpmmpsl (kvnkszdaht, buiutaisdb - kljpcqleko) View more	-	23 Oct 2019
NCT02175225 (i-DEF Trial \| i-DEF, CTgov)	Phase 2	Cerebral Hemorrhage	294	Deferoxamine Mesylate (Deferoxamine Mesylate)	vfulcbgvef = xyfdyypfki njukltpnpg (zsxpsjqzyi, gtpbbozeyj - jqfhwjhsrz) View more	-	30 May 2019
				Placebo (for Deferoxamine Mesylate) (Normal Saline)	vfulcbgvef = isyqejzgtq njukltpnpg (zsxpsjqzyi, cskzwtyych - paqydmsvlj) View more
NCT01662895 (HIDEF \| Hi-Def, CTgov)	Phase 2	Cerebral Hemorrhage	42	Deferoxamine (Deferoxamine)	uvbmlhzirc = hjsjjuerbp wstnylirmw (ocfewydloc, uspgrrhaew - wlpavuaopc) View more	-	30 May 2019
				Normal saline (Normal Saline)	uvbmlhzirc = jusoykvesg wstnylirmw (ocfewydloc, fawdmwwbgy - bbmwclqcln) View more
NCT02175225 (Pubmed) Manual	Phase 2	Cerebral Hemorrhage	291	Deferoxamine mesylate	nfkgkllyac(gdvbiqibwc) = ukhdxrurhr tstlopvkzq (qqvuwpwsyj ) View more	Negative	01 May 2019
				Placebo	nfkgkllyac(gdvbiqibwc) = nktafxiavk tstlopvkzq (qqvuwpwsyj ) View more
NCT00749515 (CTgov)	Phase 4	Beta-Thalassemia \| Transfusion-dependent Thalassemia \| Anemia, Sickle Cell	15	deferasirox (Inadequate Responders)	ipocilyuyf(cxongsdkxr) = rfcqyiwugf dkpnejjvbo (gmirkaxtbb, 259.42) View more	-	06 Feb 2019
				deferasirox (Adequate Responders (Control))	ipocilyuyf(cxongsdkxr) = xpqsqgfsgv dkpnejjvbo (gmirkaxtbb, 63.4) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis